Review Article

PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion

Sebastian Seufert,1 Roland Coras,2 Christian Tränkle,3 Darius P. Zlotos,4 Ingmar Blümcke,2 Lars Tatenhorst,5 Michael T. Heneka,5 and Eric Hahnen1

1 Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener Street 34, 50931 Cologne, Germany
2 Institute of Neuropathology, University of Erlangen, Germany
3 Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany
4 Pharmaceutical Institute, University of Würzburg, 97074 Würzburg, Germany
5 Department of Neurology, University of Bonn, 53105 Bonn, Germany

Correspondence should be addressed to Eric Hahnen, hahnen@rocketmail.com

Received 21 April 2008; Accepted 2 June 2008

Today, there is increasing evidence that PPARγ agonists, including thiazolidinediones (TDZs) and nonthiazolidinediones, block the motility and invasiveness of glioma cells and other highly migratory tumor entities. However, the mechanism(s) by which PPARγ activators mediate their antimigratory and anti-invasive properties remains elusive. This letter gives a short review on the debate and adds to the current knowledge by applying a PPARγ inactive derivative of the TDZ troglitazone (Rezulin) which potently counteracts experimental glioma progression in a PPARγ-independent manner.

Gliomas are the most common primary tumors in the central nervous system, with glioblastomas as the most malignant entity [1]. Despite multimodal therapy regimens including neurosurgical resection, radio- and polychemotherapy, the prognosis of glioma patients remains poor. Less than 3% of affected patients survive more than five years after diagnosis [2]. Rapid proliferation, tumor-induced neurodegeneration, and brain edema [3] as well as diffuse brain invasion are pathological hallmarks of these tumors and are likely to determine unfavorable prognosis. Because local invasion of neoplastic cells into the surrounding brain is perhaps the most important aspect in the biology of gliomas that preclude successful treatment, pharmacological inhibition of glioma cell migration and brain invasion is considered as a highly promising strategy for adjuvant glioma therapy.

Today, there is increasing evidence that PPARγ agonists, including thiazolidinediones (TDZs) and nonthiazolidinediones, block the motility and invasiveness of glioma cells and other highly migratory tumor entities. GW7845, an investigational non-TDZ PPARγ ligand, binds and activates human PPARγ at low nanomolar concentrations and thus possesses a higher potency than TDZs such as pioglitazone (Actos), troglitazone (Rezulin), rosiglitazone (Avandia), and the experimental PPARγ agonist ciglitazone, respectively, which require submicromolar doses [4]. Grommes et al. [5] demonstrated that 30 μM concentrations of GW7845 reduced the viability of rat (C6) and human glioma cells (U-87 MG, A172), which could be attributed to a G1 cell cycle arrest and increased cell death. Besides its antiproliferative and cytotoxic properties, the authors demonstrated for the first time that GW7845 counteracts migration and invasion of C6 rat glioma cells in vitro (spheroid outgrowth, Boyden chamber assay). A subsequent study revealed that the FDA-approved TDZ pioglitazone exhibits antiglioma properties similar to GW7845 [6]. Alike GW7845, micromolar doses of pioglitazone (30 μM) counteract C6 rat glioma cell invasiveness in vitro (Boyden chamber assay). In this study, Grommes et al. [6] demonstrated profound in vivo antiglioma properties of pioglitazone. Following C6 glioma cell implantation into the striata of adult rats, oral or intracerebral drug application effectively decelerated glioma progression, resulting in an improved clinical
outcome and 80% reduction of tumor volume at 3 weeks after tumor implantation. Immunohistochemical analyses of pioglitazone-treated animals revealed that protein levels of MMP-9 (matrix metalloproteinase 9), which has shown to be intimately involved in glioma migration and invasion [7], were substantially reduced in the bulk tumor and the tumor margins. However, the data regarding the anti-glioma properties of pioglitazone are somewhat contradictory in a mouse glioma model (GL261 glioma cells, C57Bl/6 mice). Grommes et al. demonstrated that oral application of pioglitazone increased the number of surviving animals after 30 days of treatment. By employing the same model, Spagnolo and coworkers observed no effect on survival following oral drug application, while intracerebral injection of pioglitazone increased the mean survival time [8]. We have recently shown that the TDZ troglitazone reduces the viability and proliferation of rat (F98), mouse (SMA-560), and human (U-87 MG) glioma cells slightly but significantly more potent than the remaining TZDs tested (troglitazone > pioglitazone > rosiglitazone > ciglitazone) [9]. By employing an ex vivo glioma invasion model [10], troglitazone effectively blocked glioma progression and brain invasion and consistent with the in vitro data presented by Grommes and coworkers, we confirmed that troglitazone (30 μM) antagonized rat F98 glioma cell migration (scratch wound healing, Boyden chamber assay).

Inhibition of cell motility and invasiveness by PPARγ activators has also been described for other neoplastic cells and thus appears not to be restricted to glioma. Liu et al. [14] showed that GW78845 (5 μM) as well as the FDA-approved TDZs pioglitazone and rosiglitazone (both 25 μM) inhibits the invasive properties of human MDA-MB-231 breast cancer cells. In this study, treatment with PPARγ agonists was associated with increased tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) mRNA and protein levels, which are likely to contribute to the anti-invasive effects observed. Recently, Yang et al. [15] demonstrated that troglitazone (10–30 μM) inhibits migration and invasiveness of a human ovarian carcinoma ES-2 cells. Anti-invasive properties were also shown for the TDZ ciglitazone, although with a lower potency. Extended analyses by Yang et al. revealed that troglitazone (20 μM) inhibits focal adhesion formation associated with reduced focal adhesion kinase (FAK) activity. FAK, an ubiquitously expressed nonreceptor tyrosine kinase, has shown to be a vitally important regulator of cancer cell migration and invasion. FAK is highly expressed in many tumor entities and activated by autophosphorylation [16], which has shown to be reduced by more than 80% in troglitazone-treated ES-2 cells [15]. Based on these data, the authors concluded that troglitazone may inhibit ES-2 cell migration and invasion by preventing FAK activation. Concordantly, inhibition of FAK kinase activity by the investigational small molecule TAE226 reduced the invasive properties of human U-87 MG, U251, and LN18 glioma cells by more than 50% [17], suggesting that FAK activation decisively promotes migration and invasion also of glioma cells. In all, these data demonstrate that PPARγ activators belonging to different chemical classes effectively diminish glioma progression in vitro, ex vivo, and in vivo [5, 6, 9], which occurs at least in part by the inhibition of glioma cell migration and invasiveness.

Given the fact that cancer cell migration and invasion are highly complex processes [18], the mechanism(s) by which PPARγ agonists exert their antimigratory and anti-invasive properties requires further investigation. Besides MMP-9, TIMP-1, and FAK, which have been shown to be involved in the antimigratory activities of PPARγ agonists, we recently demonstrated that already low doses of troglitazone block transforming growth factor beta (TGF-β) release [9], a cytokine which plays a pivotal role in glioma cell motility [19]. Several in vitro studies revealed that exogenously added TGF-β1 and TGF-β2 elicit a strong stimulation of migration in a variety of glioma cells [20–23], while TGF-β gene silencing has shown to reduce glioma cell motility and invasiveness [24]. In agreement with these findings, inhibition of TGF-β signaling by the investigational type I TGF-β receptor antagonist, SB-431542 reduced the invasive properties of human D-54 MG and rat F98 glioma cells by approximately 70% [9, 25]. The role of TGF-β as molecular target for glioma therapy has been facilitated by studies using surgically resected glioma tissues, which revealed an intriguing correlation between tumor grade and the expression of TGF-β ligands and their corresponding receptors I and II. High-grade gliomas express high levels of TGF-βRI, TGF-βRII, and TGF-β ligands, while the expression levels of these molecules have been shown to be weak in low-grade gliomas and normal brain tissue [26–28]. A comprehensive transcriptome-wide study by Demuth et al. [29] using 111 glial tumor samples and 24 normal brain specimens identified the TGF-β signaling pathway to be predominantly enriched in glial tumors compared to normal brain. In all, these data implicate that glioma cells release TGF-β ligands at high doses and fortify their promigratory and proinvasive properties in an autocrine manner, thus promoting glioma progression. Given the fact that 10 μM doses of troglitazone allay TGF-β release of glioma cells (F98, SMA-560, U-87 MG) by more than 50% [9], we hypothesized that the abrogation of glioma cell motility and invasiveness by troglitazone and other PPARγ activators is primarily driven by the inhibition of TGF-β signaling and thus, troglitazone and related compounds may be considered for adjuvant glioma therapy to counteract TGF-β-mediated brain invasion.

However, the mechanism(s) by which PPARγ activators mediate their antimigratory and anti-invasive properties remains elusive. We have shown that PPARγ inhibition by the investigational antagonist GW9662, either alone or in combination with troglitazone, does not affect rat F98 glioma cell invasiveness in a Boyden chamber assay, suggesting that the effects observed are not mediated by PPARγ [9]. Simultaneously, Yang and coworkers [15] have shown that PPARγ knockdown by siRNA did not counteract the anti-invasive features of troglitazone using human ovarian carcinoma ES-2 cells, underscoring the idea that the PPARγ agonists counteract cancer cell migration by a yet unknown off-target activity. To validate these preliminary findings, we analyzed the effects of a troglitazone derivative, Δ2-troglitazone, which has been shown to be PPARγ-inactive
Figure 1: Troglitazone (TRO) and the PPARγ inactive Δ2-troglitazone (Δ2-TRO) reduce glioma cell viability and TGF-β₁ release. Δ2-TRO was synthesized as previously described in [11]. (a), (c) Concentration-dependent inhibition of glioma cell viability by TRO (a) or Δ2-TRO (c) in the indicated cell lines are given as mean ± SEM percentage relative to time- and solvent-matched controls. Cell viability assays (MTT assay, 96 hours) were performed as described earlier [12, 13]. Inhibitory concentrations IC₅₀ and IC₉₀, defined as concentrations shown to inhibit tumor cell viability by 50% or 90%, respectively, were determined by nonlinear regression data analysis: TRO: F98 (62 μM, 166 μM), SMA-560 (26 μM, 407 μM), U-87 MG (120 μM, 324 μM), and U-373 MG (123 μM, 331 μM); Δ2-TRO: F98 (46 μM, 95 μM), SMA-560 (23 μM, 93 μM), U-87 MG (78 μM, 132 μM), and U-373 MG (71 μM, 126 μM). Troglitazone and the PPARγ inactive Δ2-troglitazone reduce TGF-β₁ release at low micromolar doses: (b), (d) quantification of TGF-β₁ release by F98, SMA-560, U87-MG, and U-373 MG glioma cell culture supernatants following TRO (b) or Δ2-TRO (d) treatment for 48 hours. TGF-β₁ protein levels in glioma cell culture supernatants were determined as described in [9] using the mouse/rat/porcine/canine or the human quantikine TGF-β₁ ELISA Kit (R&D Systems, Minneapolis, Minn, USA), respectively. Each experiment was repeated at least 3 times (n ≥ 3). Drug concentrations shown to inhibit TGF-β₁ release by 50% or 90%, respectively, were determined by nonlinear regression data analysis: TRO: F98 (7 μM, 11 μM), SMA-560 (8 μM, 15 μM), U-87 MG (8 μM, 28 μM), and U-373 MG (10 μM, 30 μM); Δ2-TRO: F98 (3 μM, 5 μM), SMA-560 (3 μM, 8 μM), U-87 MG (4 μM, 14 μM), and U-373 MG (4 μM, 14 μM). Δ2-Troglitazone displays higher potencies than troglitazone. Using IC₉₀ concentrations of Δ2-TRO and equimolar concentrations of TRO, the PPARγ inactive Δ2-TRO displays a significantly stronger effect in both experimental paradigms (*** = P < .001, t-test) (e), (f).
et al. [25] have shown that secretion of activated TGF-β troglitazone can be regarded as moderate. In a concentration-dependent manner with similar potency TGF-β1 release by glioma cells. Hjelmeland et al. [25] have shown that secretion of activated TGF-β1 is a common attribute of glioma cells (U-87 MG, U-373 MG, D-54 MG, D-270 MG, D-423 MG, D-538 MG), while simultaneous release of TGF-β2 was found only sporadically (D-54 MG, U-373 MG, D-423 MG). In accordance with these findings, quantification of TGF-β1 and TGF-β2 transcript levels by real-time PCR revealed that U-373 MG and SMA-560 glioma cells express both TGF-β1 and TGF-β2, respectively, while TGF-β1 is clearly the predominant isoform in F98 and U-87 MG glioma cells (data not shown). Repeated quantification (n ≥ 7) of absolute TGF-β1 levels following cultivation of glioma cells for 48 hours in serum-free medium revealed that all cell lines investigated secrete TGF-β1 (F98: 8.45 ± 1.59 ng/mL; SMA-560: 2.7 ± 0.54 ng/mL; U-87 MG: 2.55 ± 0.68 ng/mL, U-373 MG: 0.43 ± 0.08 ng/mL), while both troglitazone and Δ2-troglitazone inhibit TGF-β1 release in a dose-dependent manner (Figures 1(b), 1(d)). The finding that Δ2-troglitazone counteracts TGF-β1 release indicates that this effect is not PPARγ dependent. Again, Δ2-troglitazone displays a significantly higher potency as compared with troglitazone (Figure 1(f)). In case of Δ2-troglitazone, 90% inhibition of TGF-β1 release was found at concentrations ranging from 5 μM (F98) to 14 μM (U-87 MG, U-373 MG), whereas troglitazone required 11 μM (F98) to 30 μM (U-373 MG) to achieve the same effects. Strikingly, troglitazone as well as Δ2-troglitazone is approximately 10 fold more potent inhibitors of TGF-β1 release than of glioma cell proliferation, suggesting that both effects may not be essentially interlinked.

In agreement with the finding that TGF-β1 promotes glioma cell migration and brain invasion, treatment of glioma cells with micromolar doses of Δ2-troglitazone effectively blocks their migrative properties (Figure 2). Already 10 μM doses of Δ2-troglitazone inhibit F98 glioma cell migration in a Boyden chamber assay, while migration was completely suppressed at 20 μM. An intriguing question is whether inhibition of glioma cell migration alone is sufficient to counteract glioma progression. To address this issue we employed rat organotypic hippocampal brain slice cultures (OHSCs) to monitor glioma progression and brain invasion in the organotypic brain environment [12]. Here, eGFP-labelled F98 glioma cells were implanted into the entorhinal cortex of OHSCs (Figure 3(a)). The tumor infiltration area was quantified up to 12 days by fluorescence microscopy. A continuous increase of the bulk tumor mass was observed in solvent-matched control experiments at all time periods. 12 days after glioma cell implantation, the tumor infiltration area increased approximately 4.5 fold compared to the initial tumor size at day 1 after implantation (Figures 3(b), 3(c)). In contrast, the tumor infiltration size...
Figure 3: Δ2-Troglitazone inhibits glioma progression in an organotypic glioma transplantation model. (a) Organotypic hippocampal glioma invasion assay was performed as described earlier [10, 12, 30]. In brief, enhanced green fluorescent protein (eGFP) positive F98 rat glioma cells were transplanted into the entorhinal cortex of organotypic rat brain slice cultures one day after preparation. DAI = days after implantation. DG = dentate gyrus. EC = entorhinal cortex. (b) Tumor progression was monitored by fluorescent microscopy over the time course of 12 days. Quantification of the tumor infiltration area at day 1 to day 12 after transplantation derived from 3 independent experiments is shown. For each experiment, the tumor infiltration area at DAI 1 was defined as 100%. Data are given as mean ± SD percentage. At DAI 12, the tumor infiltration area significantly increased to 448 ± 71 % (P = .002, t-test) in solvent-matched controls but remained unchanged following Δ2-TRO treatment (75 ± 22 %; P = .18, t-test). Starting from DAI 2, differences in tumor progression (TRO versus Δ2-TRO) reached statistical significance (P < .01, t-test) (c) A continuous increase of the bulk tumor masses was observed in solvent-matched controls while 10 μM concentrations of Δ2-TRO effectively blocked tumor progression. Right column: magnification of the indicated border area between bulk tumor mass and rat brain tissue. In controls, F98 glioma cells have diffusely migrated into the adjacent brain parenchyma, while a sharp tumor border was observed following Δ2-TRO treatment (scale bar: 200 μm).

remained stable over the period of 12 days after treatment with 10 μM Δ2-troglitazone. This finding indicates that Δ2-troglitazone is not able to reduce existing tumor masses, but effectively inhibits tumor progression and brain invasion in an organotypic environment. Given the fact that 10 μM doses of Δ2-troglitazone significantly affect TGF-β1 release (Figure 1(d)) and glioma cell motility (Figure 2) but not glioma cell viability (Figure 1(c)), these data suggest that glioma cell migration is an essential requirement for glioma progression in a system closely resembling extracellular matrix environment present in the brain.

TGF-β antagonism is considered as a therapeutic strategy including the development of antisense regimens, inhibition of pro-TGF-β processing, scavenging of TGF-β by the TGF-β-binding proteoglycan decorin, and blocking of TGF-β receptor I kinase activity [33]. The finding that troglitazone and its derivative Δ2-troglitazone effectively inhibit TGF-β release suggests readily available PPARγ activators and structurally related PPARγ inactive compounds as candidate drugs for adjuvant glioma therapy. Besides its promigratory and proinvasive activities, TGF-β is considered as one of the most potent immunosuppressive factors released by gliomas.
allowing glioma cells to escape from immune surveillance [34, 35]. Friese et al. [24] demonstrated that combined TGF-β1 and TGF-β2 knock down in human LNT-229 glioma cells results in a loss of tumorigenicity when xenografted into CD1 nude mice, and natural killer cells isolated from these animals show an activated phenotype. More than 10 years ago, Ständer et al. [36] have shown that inhibition of TGF-β signaling by decorin increases the number of B and T cells (CD45+), T helper cells (CD4+), cytotoxic T cells (CD8+), and, most prominently, of activated T cells (CD25+) infiltrating the tumor in an intracerebral C6 rat glioma model. By employing an SMA-560 mouse glioma model, Tran et al. [37] have shown that inhibition of TGF-β signaling by the TGF-β RI kinase inhibitor SX-007 increased T-cell (CD3+) infiltration into the tumor. Due to the fact that inhibition of TGF-β signaling has been shown to enhance antitumor immune responses in vivo [24, 36, 37] it appears likely that troglitazone, inhibiting TGF-β release at clinically achievable doses [9, 38], restores immune surveillance. However, the yet-unknown protein/proteins mediating the inhibition of glioma progression by troglitazone and Δ2-troglitazone remain(s) to be identified and may represent future targets for structure-relationship studies. Moreover, PPARγ inactive derivatives of known PPARγ agonists which retain their propensity to counteract glioma progression might be further developed to minimize potential PPARγ mediated side effects in glioma patients.

ACKNOWLEDGMENTS

SMA-560 mouse glioma cells [39] were kindly provided by D. D. Bigner (Durham, USA). Thanks are due to Anita Betz, University of Würzburg for her skilful assistance in synthesizing Δ2-troglitazone. This study was supported by the Köln Fortune Program (Faculty of Medicine, University of Cologne) and the Wilhelm Sander-Stiftung (2008.010.1) to E. H.

REFERENCES

[1] L. M. DeAngelis, "Brain tumors," New England Journal of Medicine, vol. 344, no. 2, pp. 114–123, 2001.
[2] H. Ohgaki and P. Kleihues, "Epidemiology and etiology of gliomas," Acta Neuropathologica, vol. 109, no. 1, pp. 93–108, 2005.
[3] N. E. Savaskan, A. Heckel, E. Hahnen, et al., "Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema," Nature Medicine, vol. 14, no. 6, pp. 629–632, 2008.
[4] J. E. Cobb, S. G. Blanchard, E. G. Boswell, et al., "N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent," Journal of Medicinal Chemistry, vol. 41, no. 25, pp. 5035–5069, 1998.
[5] C. Grommes, G. E. Landreth, U. Schlegel, and M. T. Heneka, "The nonhizandinedione tyrosine-based peroxisome proliferator-activated receptor y ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells," Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 2, pp. 806–813, 2005.
[6] C. Grommes, G. E. Landreth, M. Sastre, et al., "Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment," Molecular Pharmacology, vol. 70, no. 5, pp. 1524–1533, 2006.
[7] S. S. Lakka, M. Rajan, C. Gondi, et al., "Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion," Oncogene, vol. 21, no. 52, pp. 8011–8019, 2002.
[8] A. Spagnolo, R. P. Glück, H. Lin, E. P. Cohen, D. L. Feinstein, and T. Lichtor, "Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-γ thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts," Journal of Neurosurgery, vol. 106, no. 2, pp. 299–305, 2007.
[9] R. Coras, A. Hölsken, S. Seufert, et al., "The peroxisome proliferator-activated receptor-γ agonist troglitazone inhibits transforming growth factor-β-mediated glioma cell migration and brain invasion," Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1745–1754, 2007.
[10] I. Y. Eyüpoglu, E. Hahnen, A. Heckel, et al., "Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model: technical note," Journal of Neurosurgery, vol. 102, no. 4, pp. 738–744, 2005.
[11] Y.-H. Fan, H. Chen, A. Natarajan, et al., "Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium," Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 10, pp. 2547–2550, 2004.
[12] I. Y. Eyüpoglu, E. Hahnen, R. Buslei, et al., "Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo," Journal of Neurochemistry, vol. 93, no. 4, pp. 992–999, 2005.
[13] T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983.
[14] H. Liu, C. Zang, M. H. Fenner, K. Possinger, and E. Elstner, "PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro, " Breast Cancer Research and Treatment, vol. 79, no. 1, pp. 63–74, 2003.
[15] Y.-C. Yang, T.-C. Ho, S.-L. Chen, H.-Y. Lai, J.-W. Wu, and Y.-P. Tsao, "Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line," BMC Cancer, vol. 7, no. 1, p. 216, 2007.
[16] M. J. van Nimwegen and B. van de Water, "Focal adhesion kinase: a potential target in cancer therapy," Biochemical Pharmacology, vol. 73, no. 5, pp. 597–609, 2007.
[17] T.-J. Liu, T. LaFortune, T. Honda, et al., "Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo," Molecular Cancer Therapeutics, vol. 6, no. 4, pp. 1357–1367, 2007.
[18] T. Demuth and M. E. Berens, "Molecular mechanisms of glioma cell migration and invasion," Journal of Neuro-Oncology, vol. 70, no. 2, pp. 217–228, 2004.
[19] W. Wick, M. Platten, and M. Weller, "Glioma cell invasion: regulation of metalloproteinase activity by TGF-β," Journal of Neuro-Oncology, vol. 53, no. 2, pp. 177–185, 2001.
[20] A. Merzak, S. McCrea, S. Koocheckpour, and G. J. Pilkington, "Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β1," British Journal of Cancer, vol. 70, no. 2, pp. 199–203, 1994.
[21] M. Platten, W. Wick, C. Wild-Bode, S. Aulwurm, J. Dichgans, and M. Weller, “Transforming growth factors $\beta_1$ (TGF-$\beta_1$) and TGF-$\beta_2$ promote glioma cell migration via up-regulation of $\alpha(v)\beta_3$ integrin expression,” *Biochemical and Biophysical Research Communications*, vol. 268, no. 2, pp. 607–611, 2000.

[22] W. Wick, C. Grimmel, C. Wild-Bode, M. Platten, M. Arpin, and M. Weller, “Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-$\beta_2$,” *The Journal of Neuroscience*, vol. 21, no. 10, pp. 3360–3368, 2001.

[23] M. Uhl, S. Aulwurm, J. Wischhusen, et al., “SD-208, a novel transforming growth factor $\beta$ receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo,” *Cancer Research*, vol. 64, no. 21, pp. 7954–7961, 2004.

[24] M. A. Friese, J. Wischhusen, W. Wick, et al., “RNA interference targeting transforming growth factor-$\beta$ enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo,” *Cancer Research*, vol. 64, no. 20, pp. 7956–7963, 2004.

[25] M. D. Hjelmeland, A. B. Hjelmeland, S. Sathornsumetee, et al., “SB-431542, a small molecule transforming growth factor-$\beta$-receptor antagonist, inhibits human glioma cell line proliferation and motility,” *Molecular Cancer Therapeutics*, vol. 3, no. 6, pp. 737–745, 2004.

[26] C. Kjellman, S. P. Olofsson, O. Hansson, et al., “Expression of TGF-$\beta$ isoforms, TGF-$\beta$ receptors, and Smad molecules at different stages of human glioma,” *International Journal of Cancer*, vol. 89, no. 3, pp. 251–258, 2000.

[27] T. Kawataki, H. Naganuma, A. Sasaki, H. Yoshikawa, K. Tasaka, and H. Nukui, “Correlation of thrombospondin-1 and transforming growth factor-$\beta$ expression with malignancy of glioma,” *Neuropathology*, vol. 20, no. 3, pp. 161–169, 2000.

[28] N. Yamada, M. Kato, H. Yamashita, et al., “Enhanced expression of transforming growth factor-$\beta$ and its type-I and type-II receptors in human glioblastoma,” *International Journal of Cancer*, vol. 62, no. 4, pp. 386–392, 1995.

[29] T. Demuth, J. L. Rennert, D. B. Hoelzinger, et al., “Glioma cells on the run-the migratory transcriptome of 10 human glioma cell lines,” *BMC Genomics*, vol. 9, article 54, 2008.

[30] I. Y. Eyupoglu, E. Hahnen, C. Trankle, et al., “Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275,” *Molecular Cancer Therapeutics*, vol. 5, no. 5, pp. 1248–1255, 2006.

[31] C.-W. Shiau, C.-C. Yang, S. K. Kulp, et al., “Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR,$\gamma$, *Cancer Research*, vol. 65, no. 4, pp. 1561–1569, 2005.

[32] J.-R. Weng, C.-Y. Chen, J. J. Pinzone, M. D. Ringel, and C.-S. Chen, “Beyond peroxisome proliferator-activated receptor $\gamma$ signaling: the multi-facets of the antitumor effect of thiazolidinediones,” *Endocrine-Related Cancer*, vol. 13, no. 2, pp. 401–413, 2006.

[33] W. Wick, U. Naumann, and M. Weller, “Transforming growth factor-$\beta$: a molecular target for the future therapy of glioblastoma,” *Current Pharmaceutical Design*, vol. 12, no. 3, pp. 341–349, 2006.

[34] W. Hamel and M. Westphal, “Growth factors in gliomas revisited,” *Acta Neurochirurgica*, vol. 142, no. 2, pp. 113–138, 2000.

[35] G. G. Gomez and C. A. Kruse, “Cellular and functional characterization of immuno-resistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-$\beta$,” *Journal of Immunotherapy*, vol. 30, no. 3, pp. 261–273, 2007.

[36] M. Stander, U. Naumann, L. Dumitrescu, et al., “Decorin gene transfer-mediated suppression of TGF-$\beta$ synthesis abrogates experimental malignant glioma growth in vivo,” *Gene Therapy*, vol. 5, no. 9, pp. 1187–1194, 1998.

[37] T.-T. Tran, M. Uhl, J. Y. Ma, et al., “Inhibiting TGF-$\beta$ signaling restores immune surveillance in the SMA-560 glioma model,” *Neuro-Oncology*, vol. 9, no. 3, pp. 259–270, 2007.

[38] C.-M. Loi, M. Young, E. Randinitis, A. Vassos, and J. R. Koup, “Clinical pharmacokinetics of troglitazone,” *Clinical Pharmacokinetics*, vol. 37, no. 2, pp. 91–104, 1999.

[39] J. H. Sampson, D. M. Ashley, G. E. Archer, et al., “Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion,” *Neurosurgery*, vol. 41, no. 6, pp. 1365–1373, 1997.